Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,372.00-2.51%ETH$2,574.91-4.55%GOLD$4,130.50-0.25%OIL$89.24+1.09%
Smart Investors Daily
SID Premium
Elutia Inc. logo

NASDAQ · ELUT

Elutia Inc.

Healthcare · Biotechnology

$0.82

Up+$0.04 (+5.56%)

Updated Oct 8, 2026, 4:10 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
29.77M
P/E ratio
-1.08
Dividend yield
0.00%
52-week range
$0.67 – $1.28
Volume
261.07K
Avg. volume
280.43K

Price performance · ELUT

ELUT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

ELUT closed at $0.82 after 21 trading sessions, up 2.50% for the selected period.

Last close
$0.82
Period change
+2.50%
Period low
$0.78
Period high
$0.87
Daily close
View OHLC price history
ELUT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$0.79$0.8398$0.7701$0.8201261.07K
Oct 6, 2026$0.807$0.83$0.7667$0.7769282.86K
Oct 5, 2026$0.78$0.8314$0.7199$0.8216256.24K
Oct 2, 2026$0.778$0.82$0.67$0.77871.3M
Oct 1, 2026$0.79$0.81$0.79$0.806.05M
Sep 30, 2026$0.7922$0.81$0.79$0.7921.88K
Sep 29, 2026$0.801$0.8235$0.789$0.78911.46K
Sep 28, 2026$0.825$0.83$0.81$0.815.64K
Sep 25, 2026$0.8201$0.8335$0.81$0.819834.66K
Sep 24, 2026$0.8999$0.8999$0.82$0.8316.62K
Sep 23, 2026$0.85$0.8749$0.85$0.868319.73K
Sep 22, 2026$0.852$0.852$0.80$0.810264.97K
Sep 21, 2026$0.851$0.8701$0.85$0.853423.2K
Sep 18, 2026$0.885$0.885$0.85$0.8532.49K
Sep 17, 2026$0.8566$0.8889$0.8201$0.8579.72K
Sep 16, 2026$0.83$0.83$0.7865$0.8118.23K
Sep 15, 2026$0.7739$0.8499$0.7739$0.8015.82K
Sep 14, 2026$0.785$0.8648$0.785$0.78567.96K
Sep 11, 2026$0.817$0.828$0.77$0.8125.02K
Sep 10, 2026$0.7893$0.8899$0.7852$0.800230.8K
Sep 9, 2026$0.8201$0.9099$0.80$0.800133.5K

Latest ELUT news

The latest Smart Investors Daily articles mentioning ELUT.

Stock researchCompany · Overview

ELUT research

Overview

Company profile and research snapshot.

Company profile

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.88
Implied upside
—
Analysts
—
ELUT recent ratings
DateFirmRatingTarget
Sep 10, 2025Lake StreetBuy—
May 9, 2025Lake StreetBuy—
Mar 7, 2025Cantor FitzgeraldOverweight—
Nov 15, 2024Cantor FitzgeraldOverweight—
Sep 6, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on Septe

Yahoo · Sep 2, 2026

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences. Lake Street Capital Markets 10th Annual Big Ideas Growth ConferenceElutia will host one-on-one meetings with investors at the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By